Paul Bunn, MD, University of Colorado Cancer Center, Aurora, CO, discusses the survival rates of patients with stage IV lung cancer, which remain suboptimal. For patients who have a high PD-L1 tumor proportion score (TPS), approximately a third of patients survive 5 years after initial diagnosis, and further statistical analysis is required to assess whether co-morbidities contribute to patient mortality after the 5 year mark. Despite the lack of available therapies for patients with late stage lung cancer, Prof. Bunn highlights treatment options for early stage lung cancer including immunotherapy and tyrosine kinase inhibitors (TKIs) for patients with driver mutations. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).
Leave a reply